Uses FAPI PET/CT scans to track lung scarring over time
Tests a FAPI PET/CT scan in adults with lung fibrosis, a scarring lung disease.
Plain-language title generated from the registry record
Registry title: Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Key facts
- Where
- Brussels, BelgiumSee the site
- Phase
- Phase 2
Where in Belgium
- MedecineBrussels, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Erasme University Hospital
- Trial code
- NCT06189820
- Record updated
- 16 October 2026
- Original description
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.Read full original descriptionShow less
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
Inclusion: Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines.
Exclusion: Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study; Pregnant or nursing patients; Patients with an active lung neoplasm or any active neoplasm for blood samples.